FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Samuel Denmeade

Research Profile

Disorders

Prostatic Neoplasms

Chemicals & Drugs

Living Beings

Anatomy

Procedures

Co-author Network

Publications

TOP 3
Mostafa M Elhilali; Rosemina Merchant; Peter Pommerville; Claus G Roehrborn; Richard C Yocum; Samuel R Denmeade
Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.
Michael L Manning; Simon A Williams; Christine A Jelinek; Maya B Kostova; Samuel R Denmeade
Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma.
W Nathaniel Brennen; Shuangling Chen; Samuel R Denmeade; John T Isaacs
Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Samuel Denmeade (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mostafa M Elhilali; Rosemina Merchant; Peter Pommerville; Claus G Roehrborn; Richard C Yocum; Samuel R Denmeade
Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.
The Journal of urology 2013;189(4):1421-6.
2013: Michael L Manning; Simon A Williams; Christine A Jelinek; Maya B Kostova; Samuel R Denmeade
Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma.
Journal of immunology (Baltimore, Md. : 1950) 2013;190(6):2567-74.
2013: W Nathaniel Brennen; Shuangling Chen; Samuel R Denmeade; John T Isaacs
Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer.
Oncotarget 2013;4(1):106-17.
2012: Michael J Morris; Roberto Pili; Dana Elizabeth Rathkopf; Howard I Scher; Susan F Slovin; M Vincent; J J Chudow; Samuel R Denmeade; Mario A Eisenberger; J Farrelly; Michael A Carducci
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(10):2714-9.
2012: John T Isaacs; Jun Luo; Georges H Ndikuyeze; Lizamma Antony; Shuangling Chen; Susan P Dalrymple; Jason M D'Antonio; Samuel R Denmeade
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.
The Prostate 2012;72(14):1491-505.
2012: Emmanuel S Akinboye; Samuel R Denmeade; Bernard Kwabi-Addo; Marc D Rosen; Oladapo Bakare
Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancer.
Journal of medicinal chemistry 2012;55(17):7450-9.
2012: W Nathaniel Brennen; John T Isaacs; D Marc Rosen; Hao Wang; Samuel R Denmeade
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.
Journal of the National Cancer Institute 2012;104(17):1320-34.
2012: Michael L Manning; Simon A Williams; Maya Kostova; Samuel R Denmeade
Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.
The Prostate 2012;72(11):1233-8.
2012: Yakini Brandy; Ray J Butcher; Robert L Copeland; Samuel R Denmeade; Yasmine M Kanaan; Claudia Mouamba; Innocent Ononiwu; Vonetta Williams; Dwayne A Wright; Dolapo Adedeji; Oladapo Bakare
Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines.
Investigational new drugs 2012;30(4):1709-14.
2012: Samuel R Denmeade; John T Isaacs
Engineering enzymatically activated "molecular grenades" for cancer.
Oncotarget 2012;3(7):666-7.
2012: Samuel R Denmeade; Craig Dionne; Bora Gurel; W Nathaniel Brennen; Michael A Carducci; S Brøgger Christensen; Ingrid Dach; Susan L Dalrymple; Angelo M DeMarzo; Annastasiah Mhaka; Jesper V Møller; Poul Nissen; Claus Olesen; D Marc Rosen; George Wilding; John T Isaacs
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.
Science translational medicine 2012;4(140):140ra86.
2012: Emmanuel S Antonarakis; Michael A Carducci; Samuel R Denmeade; Mario A Eisenberger; Kathy Jelaca-Maxwell; Howard I Scher; Susan F Slovin; Martha E Vincent; Michael J Morris
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.
Cancer chemotherapy and pharmacology 2012;69(3):763-71.
2012: W Nathaniel Brennen; John T Isaacs; Samuel R Denmeade
Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.
Molecular cancer therapeutics 2012;11(2):257-66.
2011: Daniel Keizman; Jenny J Kim; Victoria Sinibaldi; JANET WALCZAK; Emmanuel S Antonarakis; Michael A Carducci; Samuel R Denmeade; Peng Huang; Mario A Eisenberger
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.
The Prostate 2011;71(15):1608-15.
2011: Simon A Williams; Robert J Cotter; John T Isaacs; Christine A Jelinek; Ivan Litvinov; Samuel R Denmeade
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.
The Prostate 2011;71(15):1595-607.
2011: Jianqing Lin; Victoria Sinibaldi; Danny Y Song; Michael A Carducci; Samuel R Denmeade; Theodore L DeWeese; Mario A Eisenberger
Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
Urologic oncology 2011;29(6):670-5.
2011: Samuel R Denmeade; Blair Egerdie; Gary Steinhoff; Rosemina Merchant; Ralph Abi-Habib; Peter Pommerville
Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
European urology 2011;59(5):747-54.
2010: Daniel Keizman; Marianna Zahurak; Victoria Sinibaldi; Michael A Carducci; Samuel R Denmeade; Charles G Drake; Roberto Pili; Emmanuel S Antonarakis; Susan Hudock; Mario A Eisenberger
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(21):5269-76.
2010: Samuel R Denmeade; John T Isaacs
Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.
The Prostate 2010;70(14):1600-7.
2010: M B Weiss; Michele Vitolo; M Mohseni; D M Rosen; Samuel R Denmeade; Ben Ho Park; David Weber; Kurtis E Bachman
Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response.
Oncogene 2010;29(33):4715-24.
2010: Simon A Williams; Yi Xu; Angelo M DeMarzo; John T Isaacs; Samuel R Denmeade
Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.
The Prostate 2010;70(7):788-96.
2010: Aaron M LeBeau; Maya Kostova; Charles S Craik; Samuel R Denmeade
Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.
Biological chemistry 2010;391(4):333-43.
2010: Daniel C Danila; Michael J Morris; Johann S de Bono; Charles J Ryan; Samuel R Denmeade; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Thian Kheoh; Christopher Haqq; Arturo Molina; Aseem Anand; Michael Koscuiszka; Steven M Larson; Lawrence H Schwartz; Martin Fleisher; Howard I Scher
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(9):1496-501.
2009: Pratap Singh; Aaron M LeBeau; Hans Lilja; Samuel R Denmeade; John T Isaacs
Molecular insights into substrate specificity of prostate specific antigen through structural modeling.
Proteins 2009;77(4):984-93.
2009: Mary-Ellen Taplin; Meredith M Regan; Yoo-Joung Ko; Glenn J Bubley; Stephen E Duggan; Lillian Werner; Tomasz M Beer; Christopher W Ryan; Paul Mathew; Shi-Ming Tu; Samuel R Denmeade; William K Oh; Oliver Sartor; Christos S Mantzoros; Roger Rittmaster; Philip W Kantoff; Steven P Balk
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):7099-105.
2009: J Lin; Samuel R Denmeade; Michael A Carducci
HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides.
Current cancer drug targets 2009;9(7):881-7.
2009: Preetika Sharma; Amy B Wisniewski; Milena Braga-Basaria; Xiaoqiang Xu; Mary Yep; Samuel R Denmeade; Adrian S Dobs; Theodore L DeWeese; Michael A Carducci; Shehzad Basaria
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.
The Journal of urology 2009;182(5):2265-72.
2009: Aaron M LeBeau; SANGEETA RAY; Martin G Pomper; RONNIE MEASE; Samuel R Denmeade
Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer.
Bioorganic & medicinal chemistry 2009;17(14):4888-93.
2009: Aaron M LeBeau; W Nathaniel Brennen; Saurabh Aggarwal; Samuel R Denmeade
Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin.
Molecular cancer therapeutics 2009;8(5):1378-86.
2009: Donald J Vander Griend; Lizamma Antony; Susan L Dalrymple; Yi Xu; S Brøgger Christensen; Samuel R Denmeade; John T Isaacs
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.
Molecular cancer therapeutics 2009;8(5):1340-9.
2009: Aaron M LeBeau; Pratap Singh; John T Isaacs; Samuel R Denmeade
Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.
Biochemistry 2009;48(15):3490-6.
2009: S Brøgger Christensen; Dorthe Mondrup Skytte; Samuel R Denmeade; Craig Dionne; Jesper Vuust Møller; Poul Nissen; John T Isaacs
A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells.
Anti-cancer agents in medicinal chemistry 2009;9(3):276-94.
2009: John P Gustin; Bedri Karakas; Michele B Weiss; Abde M Abukhdeir; Josh David Lauring; Joseph P Garay; David Peter Cosgrove; Akina Tamaki; HIROYUKI KONISHI; Yuko Konishi; Morassa Mohseni; Grace Wang; D Marc Rosen; Samuel R Denmeade; Michaela J Higgins; Michele Vitolo; Kurtis E Bachman; Ben Ho Park
Knockin of mutant PIK3CA activates multiple oncogenic pathways.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(8):2835-40.
2009: Sachin S Chandran; Simon A Williams; Samuel R Denmeade
Extended-release PEG-luciferin allows for long-term imaging of firefly luciferase activity in vivo.
Luminescence : the journal of biological and chemical luminescence 2009;24(1):35-8.
2008: Anand Singla; Samuel R Denmeade
Left posterior fascicular block due to high-dose interleukin-2.
The Annals of pharmacotherapy 2008;42(9):1340-3.
2008: Aaron M LeBeau; Pratap Singh; John T Isaacs; Samuel R Denmeade
Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen.
Chemistry & biology 2008;15(7):665-74.
2008: Dana Elizabeth Rathkopf; Michael A Carducci; Michael J Morris; Susan F Slovin; Mario A Eisenberger; Roberto Pili; Samuel R Denmeade; Moshe Kelsen; Tracy Curley; Melinda Halter; Connie Collins; Martin Fleisher; Glenn Heller; Sharyn D Baker; Howard I Scher
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(18):2959-65.
2008: Sachin S Chandran; SANGEETA RAY; RONNIE MEASE; Martin G Pomper; Samuel R Denmeade
Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA).
Cancer biology & therapy 2008;7(6):974-82.
2008: Pratap Singh; Simon A Williams; Meha Shah; Thomas Lectka; Gareth J Pritchard; John T Isaacs; Samuel R Denmeade
Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds.
Proteins 2008;70(4):1416-28.
2008: Saurabh Aggarwal; W Nathaniel Brennen; Thomas P Kole; Elizabeth Schneider; Ozlem Topaloglu; Melinda Yates; Robert J Cotter; Samuel R Denmeade
Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites.
Biochemistry 2008;47(3):1076-86.
2007: Sachin S Chandran; Anjan Nan; D Marc Rosen; Hamidreza Ghandehari; Samuel R Denmeade
A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Molecular cancer therapeutics 2007;6(11):2928-37.
2007: Connie Collins; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Alan W Partin; Roberto Pili; Victoria Sinibaldi; JANET WALCZAK; Samuel R Denmeade
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Cancer biology & therapy 2007;6(9):1360-7.
2007: Ravibhushan Singh; Jeff Browning; Ralph J Abi-Habib; Kevin Wong; Simon A Williams; Rosemina Merchant; Samuel R Denmeade; Thomas J Buckley; Arthur E Frankel
Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity.
Anti-cancer drugs 2007;18(7):809-16.
2007: Srinivas K Kumar; Simon A Williams; John T Isaacs; Samuel R Denmeade; Saeed R Khan
Modulating paclitaxel bioavailability for targeting prostate cancer.
Bioorganic & medicinal chemistry 2007;15(14):4973-84.
2007: Simon A Williams; Rosemina F Merchant; Elizabeth Garrett-Mayer; John T Isaacs; J Thomas Buckley; Samuel R Denmeade
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.
Journal of the National Cancer Institute 2007;99(5):376-85.
2007: Gopal K Bajaj; Zhe Zhang; Elizabeth Garrett-Mayer; Renee Drew; Victoria Sinibaldi; Roberto Pili; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Theodore L DeWeese
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
Urology 2007;69(3):526-31.
2007: Simon A Williams; Pratap Singh; John T Isaacs; Samuel R Denmeade
Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?
The Prostate 2007;67(3):312-29.
2007: Sushant Kachhap; Dennis Faith; Zheng (David) Qian; Shabana Shabbeer; Nathan L Galloway; Roberto Pili; Samuel R Denmeade; Angelo M DeMarzo; Michael A Carducci
The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin.
PloS one 2007;2(9):e844.
2006: Huizhen Liu; Kent Gunnertoft Jensen; Linh M Tran; Ming Chen; Lin Zhai; Carl Erik Olsen; Helmer Søhoel; Samuel R Denmeade; John T Isaacs; S Brøgger Christensen
Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganica.
Phytochemistry 2006;67(24):2651-8.
2006: Saurabh Aggarwal; Pratap Singh; Ozlem Topaloglu; John T Isaacs; Samuel R Denmeade
A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
Cancer research 2006;66(18):9171-7.
2006: P Singh; Aarti R Uzgare; Ivan V Litvinov; Samuel R Denmeade; John T Isaacs
Combinatorial androgen receptor targeted therapy for prostate cancer.
Endocrine-related cancer 2006;13(3):653-66.
2006: Victoria Sinibaldi; Kathy Elza-Brown; Jill Schmidt; Mario A Eisenberger; Eli Rosenbaum; Samuel R Denmeade; Roberto Pili; JANET WALCZAK; Sharyn D Baker; Marianna Zahurak; Michael A Carducci
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
American journal of clinical oncology 2006;29(4):395-8.
2006: Yi Xu; Susan L Dalrymple; Robyn E Becker; Samuel R Denmeade; John T Isaacs
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):4072-9.
2006: Saurabh Aggarwal; Rebecca M Ricklis; Simon A Williams; Samuel R Denmeade
Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human.
The Prostate 2006;66(9):903-10.
2006: Helmer Søhoel; Anne-Marie Lund Winther; Jesper V Møller; Poul Nissen; Samuel R Denmeade; John T Isaacs; Carl Erik Olsen; S Brøgger Christensen
Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells.
Bioorganic & medicinal chemistry 2006;14(8):2810-5.
2006: Saurabh Aggarwal; James L Harden; Samuel R Denmeade
Synthesis and screening of a random dimeric peptide library using the one-bead-one-dimer combinatorial approach.
Bioconjugate chemistry 2006;17(2):335-40.
2006: Samuel Janssen; D Marc Rosen; Rebecca M Ricklis; Craig Dionne; Hans Lilja; S Brøgger Christensen; John T Isaacs; Samuel R Denmeade
Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
The Prostate 2006;66(4):358-68.
2006: Christopher J Strock; Jong-In Park; D Marc Rosen; Bruce Ruggeri; Samuel R Denmeade; Douglas W Ball; Barry D Nelkin
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.
The Journal of clinical endocrinology and metabolism 2006;91(1):79-84.
2005: Saurabh Aggarwal; Samuel Janssen; Randy M Wadkins; James L Harden; Samuel R Denmeade
A combinatorial approach to the selective capture of circulating malignant epithelial cells by peptide ligands.
Biomaterials 2005;26(30):6077-86.
2005: Pratap Singh; Annastasiah Mhaka; S Brøgger Christensen; Jeffrey J Gray; Samuel R Denmeade; John T Isaacs
Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase.
Journal of medicinal chemistry 2005;48(8):3005-14.
2005: Samuel R Denmeade; John T Isaacs
The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer.
Cancer biology & therapy 2005;4(1):14-22.
2004: Samuel Janssen; Carsten M Jakobsen; D Marc Rosen; Rebecca M Ricklis; Ulrich Reineke; S Brøgger Christensen; Hans Lilja; Samuel R Denmeade
Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
Molecular cancer therapeutics 2004;3(11):1439-50.
2004: Annastasiah Mhaka; Alyssa M Gady; D Marc Rosen; Kin-Ming Lo; Stephen D Gillies; Samuel R Denmeade
Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA).
Cancer biology & therapy 2004;3(6):551-8.
2004: Samuel R Denmeade; John T Isaacs
The role of prostate-specific antigen in the clinical evaluation of prostatic disease.
BJU international 2004;93 Suppl 1():10-5.
2004: Rena Lapidus; Wenbin Dang; D Marc Rosen; Alyssa M Gady; Yelena Zabelinka; Robert N O'Meally; Theodore L DeWeese; Samuel R Denmeade
Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
The Prostate 2004;58(3):291-8.
2004: Samuel R Denmeade; John T Isaacs
Development of prostate cancer treatment: the good news.
The Prostate 2004;58(3):211-24.
2004: Usha Sunkara; JANET WALCZAK; Lori Summerson; Theresa Rogers; Mario A Eisenberger; Samuel R Denmeade; Roberto Pili; Carol Ann Huff; Victoria Sinibaldi; Michael A Carducci
A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2004;24(1):37-41.
2003: Christopher J Strock; Jong-In Park; Mark Rosen; Craig Dionne; Bruce Ruggeri; Susan Jones-Bolin; Samuel R Denmeade; Douglas W Ball; Barry D Nelkin
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
Cancer research 2003;63(17):5559-63.
2003: Samuel R Denmeade; Carsten M Jakobsen; Samuel Janssen; Saeed R Khan; Elizabeth Garrett-Mayer; Hans Lilja; S Brøgger Christensen; John T Isaacs
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Journal of the National Cancer Institute 2003;95(13):990-1000.
2003: Samuel R Denmeade; Ivan V Litvinov; Lori J Sokoll; Hans Lilja; John T Isaacs
Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
The Prostate 2003;56(1):45-53.
2003: Samuel R Denmeade; Lori J Sokoll; Susan L Dalrymple; D Marc Rosen; Alyssa M Gady; Debra J Bruzek; Rebecca M Ricklis; John T Isaacs
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
The Prostate 2003;54(4):249-57.
2002: Annastasiah Mhaka; Samuel R Denmeade; Wei Yao; John T Isaacs; Saeed R Khan
A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.
Bioorganic & medicinal chemistry letters 2002;12(17):2459-61.
2002: Samuel R Denmeade; John T Isaacs
A history of prostate cancer treatment.
Nature reviews. Cancer 2002;2(5):389-96.
2002: Bertrand Tombal; Samuel R Denmeade; J-M Gillis; John T Isaacs
A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis.
Cell death and differentiation 2002;9(5):561-73.
2002: Jacek Pinski; Ashani T Weeraratna; Aarti R Uzgare; Julia Arnold; Samuel R Denmeade; John T Isaacs
Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.
Cancer research 2002;62(4):986-9.
2001: Carsten M Jakobsen; Samuel R Denmeade; John T Isaacs; Alyssa M Gady; C E Olsen; S Brøgger Christensen
Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells.
Journal of medicinal chemistry 2001;44(26):4696-703.
2001: Ashani T Weeraratna; Susan L Dalrymple; J C Lamb; Samuel R Denmeade; Sheila J Miknyoczki; Craig Dionne; John T Isaacs
Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2237-45.
2001: Samuel R Denmeade; Janita Lövgren; Saeed R Khan; Hans Lilja; John T Isaacs
Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
The Prostate 2001;48(2):122-6.
2001: Samuel R Denmeade; Lori J Sokoll; Daniel W Chan; Saeed R Khan; John T Isaacs
Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
The Prostate 2001;48(1):1-6.
2000: Jean-Luc Gala; Sylvain Loric; Y Guiot; Samuel R Denmeade; Alyssa M Gady; Francis Brasseur; Michel Heusterspreute; Pascal Eschwège; Philippe de Nayer; Paul J Van Cangh; Bertrand Tombal
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):4049-54.
2000: Saeed R Khan; Samuel R Denmeade
In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
The Prostate 2000;45(1):80-3.
2000: C Jackisch; Hillary A Hahm; Bertrand Tombal; Diane E McCloskey; KA Butash; Nancy E Davidson; Samuel R Denmeade
Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2844-50.
2000: Menachem Laufer; Samuel R Denmeade; Victoria Sinibaldi; Michael A Carducci; Mario A Eisenberger
Complete androgen blockade for prostate cancer: what went wrong?
The Journal of urology 2000;164(1):3-9.
2000: Bertrand Tombal; Ashani T Weeraratna; Samuel R Denmeade; John T Isaacs
Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells.
The Prostate 2000;43(4):303-17.
1999: S Brøgger Christensen; A Andersen; H Kromann; Marek Treiman; B Tombal; Samuel R Denmeade; John T Isaacs
Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells.
Bioorganic & medicinal chemistry 1999;7(7):1273-80.
1999: Samuel R Denmeade; X S Lin; Bertrand Tombal; John T Isaacs
Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells.
The Prostate 1999;39(4):269-79.
1999: Bertrand Tombal; Samuel R Denmeade; John T Isaacs
Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosis.
Cell calcium 1999;25(1):19-28.
1999: Allen C Gao; Wei Lou; T Ichikawa; Samuel R Denmeade; J Carl Barrett; John T Isaacs
Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2.
The Prostate 1999;38(1):46-54.
1998: Samuel R Denmeade; A Nagy; J Gao; Hans Lilja; Andrew V Schally; John T Isaacs
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
Cancer research 1998;58(12):2537-40.
1998: Samuel R Denmeade; John T Isaacs
Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer.
The cancer journal from Scientific American 1998;4 Suppl 1():S15-21.
1997: IB Joseph; Joel B Nelson; Samuel R Denmeade; John T Isaacs
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 1):2507-11.
1997: X S Lin; Samuel R Denmeade; L Cisek; John T Isaacs
Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin.
The Prostate 1997;33(3):201-7.
1997: Samuel R Denmeade; Wei Lou; Janita Lövgren; Johan Malm; Hans Lilja; John T Isaacs
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.
Cancer research 1997;57(21):4924-30.
1997: Samuel R Denmeade; John T Isaacs
Prostate cancer: where are we and where are we going?
British journal of urology 1997;79 Suppl 1():2-7.
1997: Samuel R Denmeade; Diane E McCloskey; IB Joseph; Hillary A Hahm; John T Isaacs; Nancy E Davidson
Apoptosis in hormone-responsive malignancies.
Advances in pharmacology (San Diego, Calif.) 1997;41():553-83.
1996: Samuel R Denmeade; X S Lin; John T Isaacs
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.
The Prostate 1996;28(4):251-65.
1996: Samuel R Denmeade; John T Isaacs
Activation of programmed (apoptotic) cell death for the treatment of prostate cancer.
Advances in pharmacology (San Diego, Calif.) 1996;35():281-306.
1995: X Lin; Samuel R Denmeade; John T Isaacs
The genetics of programmed (apoptotic) cell death.
Cancer surveys 1995;25():173-94.